Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular Lymphoma
Carla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.
Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma (FL).
There is no clear way to distinguish which patients will do poorly after treatment, and there’s also no biomarkers to determine the response, says Casulo. With a plethora of options available, a physician might select therapy based on when the patient recurs; if a patient recurred early, those patients can be treated more aggressively, but an older patient might need to be considered for a more gentle approach.
Enasidenib Shows Promise as Post-Transplant Maintenance in IDH2-Mutated AML
January 7th 2025Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.
Read More
Could Triapine With Lutetium 177 Dotatate Improve Outcomes for Neuroendocrine Tumors?
December 30th 2024Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.
Read More
